0.5974
Schlusskurs vom Vortag:
$0.58
Offen:
$0.58
24-Stunden-Volumen:
29,834
Relative Volume:
0.42
Marktkapitalisierung:
$14.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.33M
KGV:
-1.6089
EPS:
-0.3713
Netto-Cashflow:
$-8.02M
1W Leistung:
-4.14%
1M Leistung:
-15.65%
6M Leistung:
-69.21%
1J Leistung:
-85.78%
Genenta Science Spa Adr Stock (GNTA) Company Profile
Firmenname
Genenta Science Spa Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare GNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
GNTA
Genenta Science Spa Adr
|
0.5974 | 13.68M | 0 | -7.33M | -8.02M | -0.3713 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-29 | Fortgesetzt | ROTH MKM | Buy |
| 2022-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-13 | Eingeleitet | Maxim Group | Buy |
Genenta Science Spa Adr Aktie (GNTA) Neueste Nachrichten
GNTA Stock Price, Quote & Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta Science Ends Ospedale San Raffaele License to Refocus Strategy - TipRanks
GNTA Stock Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta Science to close US subsidiary and transition CFO to consulting role - Investing.com Canada
Genenta Science to close US subsidiary and transition CFO to consulting role By Investing.com - Investing.com South Africa
Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role - TipRanks
Genenta Science Moves Into Aerospace With Majority Investment Deal for Sòphia High Tech - The Globe and Mail
Genenta signs Definitive Agreements with Sophia High Tech - GlobeNewswire Inc.
Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance - The Globe and Mail
Genenta Science receives Nasdaq notice on minimum bid price compliance By Investing.com - Investing.com India
Genenta Science receives Nasdaq notice on minimum bid price compliance - Investing.com
What's going on in today's pre-market session - chartmill.com
Genenta Moves to Acquire Control of Italian Space-Defense Supplier Sòphia High Tech - TipRanks
Genenta Science Cancels Late-March Vote on Rebrand to Saentra Forge - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business - Finviz
11 Best Italian Stocks to Buy in 2026 - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Prenetics Group (PRE) - The Globe and Mail
Genenta Science Piv A Strategic Shift from Biotech to Defense - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Genenta Science stock soars on strategic pivot to defense sector By Investing.com - Investing.com Australia
Genenta Science stock soars on strategic pivot to defense sector - Investing.com
Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator - TipRanks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and BioLife Solutions (BLFS) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Trading Up 0.7% – Here’s What Happened - Defense World
Operating cash flow per share of Genenta Science SpA Sponsored ADR – FWB:K5F - TradingView — Track All Markets
Return on equity % of Genenta Science SpA Sponsored ADR – LSX:A3C9EK - TradingView
Healthy Upside Potential: Genenta Science SpA ADR (GNTA) - Setenews
Genenta Science stock soars after update on glioblastoma treatment study By Investing.com - Investing.com Australia
Genenta Science stock soars after update on glioblastoma treatment study - Investing.com
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell? - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX) - The Globe and Mail
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - inkl
Genenta Science Secures $15 Million in Registered Direct Offering - TipRanks
Genenta Science Appoints New Board Member and Confirms CEO - TipRanks
These stocks are moving in today's pre-market session - ChartMill
Genenta Science Soars Following Strategic Collaboration with Anemocyte - StocksToTrade
Genenta Science Stock Skyrockets After Strategic Collaboration Announcement - StocksToTrade
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), AnaptysBio (ANAB) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development - TipRanks
Genenta Science announces amendment to pact with AGC Biologics - TipRanks
Finanzdaten der Genenta Science Spa Adr-Aktie (GNTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):